Literature DB >> 1352456

Multiple endocrine neoplasia type 2 with malignant pheochromocytoma--long term follow-up of a case by 131I-meta-iodobenzylguanidine scintigraphy.

H Namba1, H Kondo, S Yamashita, H Kimura, N Yokoyama, M Tsuruta, A Sato, M Izumi, H Kinoshita, S Hakariya.   

Abstract

The case of a 33-year-old Japanese man, who has Multiple Endocrine Neoplasia Type 2 (MEN IIa) (Sipple's syndrome) with malignant pheochromocytoma, is reported. He had survived for twelve years since the initial diagnosis of malignant pheochromocytoma. Within this period, he had undergone 131I-meta-iodobenzylguanidine scintigraphy twice, in 1983 and 1990. This is the first case in Japan of a longterm surviving patient with malignant pheochromocytoma followed up by 131I-MIBG scintigraphy. Although he had no exacerbation of clinical symptoms or urinary catecholamine levels, second scintigraphy clearly showed an increase in the tumor size, new metastasis of the malignant pheochromocytoma and exacerbation of the medullary thyroid carcinoma. Compared with any other roentgenological device and hormonal data, 131I-MIBG scintigraphy was seen to be a good tool for evaluating the localization and the progression of tumors. 131I-MIBG scintigraphy is a useful procedure not only for initial diagnosis but also for judging progression in a case of advanced malignant pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352456     DOI: 10.1007/bf03164652

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  20 in total

1.  CT for pheochromocytoma diagnosis.

Authors:  K Laursen; K Damgaard-Pedersen
Journal:  AJR Am J Roentgenol       Date:  1980-02       Impact factor: 3.959

2.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

3.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.

Authors:  E L Bravo; R C Tarazi; R W Gifford; B H Stewart
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

Review 4.  Update on basic research and clinical experience with metaiodobenzylguanidine.

Authors:  W H Beierwaltes
Journal:  Med Pediatr Oncol       Date:  1987

5.  Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterization.

Authors:  B Shapiro; J C Sisson; R Lloyd; M Nakajo; W Satterlee; W H Beierwaltes
Journal:  Clin Endocrinol (Oxf)       Date:  1984-02       Impact factor: 3.478

6.  Pheochromocytoma. A persistently problematic and still potentially lethal disease.

Authors:  D T Freier; F E Eckhauser; T S Harrison
Journal:  Arch Surg       Date:  1980-04

7.  Complementary roles of CT and 131I-MIBG scintigraphy in diagnosing pheochromocytoma.

Authors:  I R Francis; G M Glazer; B Shapiro; J C Sisson; B H Gross
Journal:  AJR Am J Roentgenol       Date:  1983-10       Impact factor: 3.959

8.  Pheochromocytoma: current status and changing trends.

Authors:  J A van Heerden; S G Sheps; B Hamberger; P F Sheedy; J G Poston; W H ReMine
Journal:  Surgery       Date:  1982-04       Impact factor: 3.982

9.  Spectrum of pheochromocytoma in multiple endocrine neoplasia. A scintigraphic portrayal using 131I-metaiodobenzylguanidine.

Authors:  T W Valk; M S Frager; M D Gross; J C Sisson; D M Wieland; D P Swanson; T J Mangner; W H Beierwaltes
Journal:  Ann Intern Med       Date:  1981-06       Impact factor: 25.391

10.  Scintigraphic localization of pheochromocytoma.

Authors:  J C Sisson; M S Frager; T W Valk; M D Gross; D P Swanson; D M Wieland; M C Tobes; W H Beierwaltes; N W Thompson
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

View more
  1 in total

1.  Metastatic pheochromocytoma in MEN 2A: A rare association.

Authors:  Rimesh Pal; Ashu Rastogi; Santosh Kumar; Anil Bhansali
Journal:  BMJ Case Rep       Date:  2018-03-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.